文献速递技术与安全PETCT

诊疗一体化综述:新兴方法与临床进展的视角

A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
PubMed 文献 · Radiol Imaging Cancer · 2023-01-01

诊疗一体化将诊断与治疗结合,近年随着美国FDA批准镥-177 DOTATATE和镥-177 PSMA载体放射性核素疗法,临床应用增多。本文综述诊疗一体化活跃临床进展的关键领域,包括推进FDA批准及新兴放射性药物的临床试验、剂量学计算方法、不同放射性核素疗法的影像、扩大现有诊疗一体化药物适应证以治疗更广泛癌症,以及该领域新兴理念。

要点

  • 诊疗一体化结合诊断与治疗,利用放射性药物或配对放射性药物对多种癌症进行成像和选择性治疗。
  • 近年美国FDA批准镥-177 DOTATATE和镥-177 PSMA载体放射性核素疗法,推动临床使用增加。
  • 综述涵盖临床试验、剂量学计算、不同放射性核素疗法影像、扩大适应证及新兴理念等关键领域。

核心结论

  • 诊疗一体化领域具有新兴临床应用的迫近潜力,本文综述了活跃临床进展的关键领域。

研究设计与样本

  • 综述文章,回顾诊疗一体化活跃临床进展的关键领域,包括临床试验、剂量学计算、影像及扩大适应证等。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Theranostics is the combination of two approaches-diagnostics and therapeutics-applied for decades in cancer imaging using radiopharmaceuticals or paired radiopharmaceuticals to image and selectively treat various cancers. The clinical use of theranostics has increased in recent years, with U.S. Food and Drug Administration (FDA) approval of lutetium 177 (177Lu) tetraazacyclododecane tetraacetic acid octreotate (DOTATATE) and 177Lu-prostate-specific membrane antigen vector-based radionuclide therapies. The field of theranostics has imminent potential for emerging clinical applications. This article reviews critical areas of active clinical advancement in theranostics, including forthcoming clinical trials advancing FDA-approved and emerging radiopharmaceuticals, approaches to dosimetry calculations, imaging of different radionuclide therapies, expanded indications for currently used theranostic agents to treat a broader array of cancers, and emerging ideas in the field. Keywords: Molecular Imaging, Molecular Imaging-Cancer, Molecular Imaging-Clinical Translation, Molecular Imaging-Target Development, PET/CT, SPECT/CT, Radionuclide Therapy, Dosimetry, Oncology, Radiobiology © RSNA, 2023.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Burkett BJ, Bartlett DJ, McGarrah PW, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023. PMID: 37477566. doi:10.1148/rycan.220157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。